

28 October 2024

# Avacta Group plc

("Avacta" or "the Group" or "the Company")

# Block Listing Six Monthly Return

Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

| Name of <i>applicant</i> :   |       | Avacta Group plc |  |                 |
|--|-------|------------------|--|-----------------|
| Name of scheme:  |       | EMI scheme       |  |                 |
| Period of return:  | From: | 28 April 2024    |  | 27 October 2024 |
| Balance of unallotted securities under scheme(s) from previous return:   |       | 803,006          |  |                 |
| <u>Plus:</u> The amount by which the block<br>scheme(s) has been increased since the date of<br>the last return (if any increase has been applied<br>for): |       | nil              |  |                 |
| Less: Number of <i>securities</i> issued/allotted<br>under scheme(s) during period (see LR3.5.7G):   |       | 527,626          |  |                 |
| Equals: Balance under scheme(s) not yet issued/allotted at end of period:  |       | 275,380          |  |                 |

| Name of applicant:   |       | Avacta Group plc |  |                 |
|--|-------|------------------|--|-----------------|
| Name of scheme:  |       | LTIP scheme      |  |                 |
| Period of return:  | From: | 28 April 2024    |  | 27 October 2024 |
| Balance of unallotted securities under scheme(s):  |       | 9,719,257        |  |                 |
| <u>Plus:</u> The amount by which the block<br>scheme(s) has been increased since the date of<br>the last return (if any increase has been applied<br>for): |       | nil              |  |                 |
| Loop Number of any witten incured/allatted   |       | 2 000 000        |  |                 |

| Less: Number of securities issuedrationed under scheme(s) during period (see LR3.5.7G): | 3,000,000 |
|---|-----------|
| Equals: Balance under scheme(s) not yet issued/allotted at end of period:               | 5,913,257 |

| Name of contact:             | James Heseltine, Company Secretary |
|------------------------------|------------------------------------|
| Telephone number of contact: | + 44 (0) 1904 217070               |

Ends-

For further information from Avacta Group plc, please contact:

# Avacta Group plc Michael Vinegrad, Group Communications https://avacta.com/ Director www.peelhunt.com Peel Hunt (Nomad and Broker) www.peelhunt.com James Steel / Chris Golden / Patrick Birkholm ICR Healthcare Wary-Jane Elliott / Jessica Hodgson / Sukaina avacta@consilium-comms.com

Virji

# About the pre|CISION<sup>®</sup> Platform

The pre|CISION<sup>®</sup> platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION<sup>®</sup> platform harnesses this tumor specific protease to cleave pre|CISION<sup>®</sup> peptide drug conjugates and pre|CISION<sup>®</sup> antibody/Affimer<sup>®</sup> drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

## About AVA6000: FAP-enabled doxorubicin

The lead pre|CISION<sup>®</sup> program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients. To register for news alerts by email go to <u>https://avacta.com/investors/investor-news-email-alerts/</u>.

## AVA6103: FAP-enabled PDC targeting Topoisomerase I

AVA6103 is a pre/CISION-enabled PDC comprised of the pre/CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability.

# AVA7100: pre|CISION<sup>®</sup> FAP Affimer Drug Conjugate (AffDC)

AVA7100 is a pre|CISION<sup>®</sup>-enabled Affimer<sup>®</sup> drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer<sup>®</sup> molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity.

AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload.

### About Avacta Group plc - https://avacta.com/

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION<sup>®</sup> platform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to <u>https://avacta.com/investors/investor-news-email-alerts/</u>.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BLRPPGPPUUPCGRM